Gynuity envisions a world in which each individual has access to safe and effective reproductive and maternal health care—delivered where, when, and how needed.
It is our mission to develop scientific, clinical and programmatic evidence in reproductive and maternal health and to advocate for its use, assuring that each individual benefits from the fruits of medical science and technology. We do this on a global scale through research, strategic partnerships, and communications for impact.
Due to COVID-19 Gynuity Health Projects is now working remotely. If you want to contact any of our staff members, please email them directly. (Staff emails are listed in our website’s staff directory.) If you want to leave a message in our attended general mailbox, please send it to firstname.lastname@example.org.
Gynuity listens to women, providers and policymakers, and works with them to create services that are safe, high quality, and person-centered. Through conversations and active collaborations, we use research to fill evidence gaps for new models of care, influence change, and advocate for improvements in policy and practice.
Our research demonstrates that simple, safe, and effective reproductive and maternal health technologies transform lives and improve outcomes for women and girls.
Through speaking, convening partners, and publishing our research, we create the synergies that trigger change in policy and practice.
Strategic communications increase the impact of our research and programmatic findings.
Expansion of a direct-to-patient telemedicine abortion service in the United States and experience during the COVID-19 pandemic
“It was close enough, but it wasn't close enough”: A qualitative exploration of the impact of direct-to-patient telemedicine abortion on access to abortion care
Provision of medication abortion in Hawai‘i during COVID-19: Practical experience with multiple care delivery models
Jen Russo and Ilana Dzuba discuss a 2020 Daniel Mishell Outstanding Article: A non-inferiority study of outpatient mifepristone-misoprostol medical abortion at 64–70 days and 71–77 days of gestationView Podcast
This toolkit provides resources for providers and health care systems to introduce service delivery that allows people choosing medical abortion the option to receive an implant or injectable contraceptive at the same time as mifepristone.View Toolkit
Gynuity has viewed mifepristone abortion as a revolutionary technology with the potential to increase autonomy and choice in the reproductive realm. Here we reflect on our work during the last two decades of increasing access to medical abortion.View reflections
Learn about Gynuity's achievements and new programmatic directions.Read the Strategic Plan
Gynuity is providing a safe and effective way for women to access medical abortion using telemedicine.Visit the TelAbortion Website
Gynuity's image bank offers illustrations that can help articulate concepts across audiences. Available for download.View the Image Bank
Learn about medical abortion commodities in dozens of countries.Explore the database
Gynuity has been at the forefront of global women’s health since 2003.See our Achievements
Gynuity's TelAbortion Media Toolkit provides messaging and graphics for the dissemination of information about the study across media channels.View Here
This short film on the history of mifepristone policy in the U.S. investigates baseless FDA restrictions and claims that overstate the danger of the drug. It’s a great refresher on the many barriers to MA access and the burden this puts onto abortion-seekers and care providers. The video features Gynuity president Beverly Winikoff.View Video
This podcast series showcases diverse perspectives on self managed abortion. Gynuity president Beverly Winikoff was interviewed for Part 3: The Abortion Pill, RU486, where she outlines its invention, introduction to the American market and how the pill moves globally.View Podcast